Metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a chronic liver condition characterized by excessive fat accumulation in the liver alongside at least one metabolic risk factor such as overweight, obesity, or type 2 diabetes. It can range in severity, with non-alcoholic steatohepatitis (NASH) indicating further liver inflammation and increased risks of complications like cirrhosis, liver cancer, and cardiovascular disease.
Health Outcomes
- Alleviated Non-Alcoholic Fatty Liver Disease
- Altered Circulating Metabolic Profile
- Altered Fatty Acid Profiles
- Altered Metabolic Profile
- Atherogenic Lipid Profile
- Change in Waist-to-Hip Ratio
- Changed Bicarbonate Level
- Characterized Carbohydrate Metabolism Enzyme Activity
- Distinct Metabolic Profile
- Elevated Plasma-Branched Chain Amino Acids
- Elevated Triglyceride Levels
- Enhanced AMPK Activation
- Enhanced Antioxidant Metabolism
- Enhanced Fatty Acid Metabolism
- Enhanced Health Promotion
- Enhanced Hepatic Fatty Acid Oxidation
- Enhanced Lipid Metabolism in Adipose Tissue
- Enhanced Metabolic Pathway Activation
- Improved Bioactivity
- Improved Biochemical Parameters
- Improved Blood Biochemical Indicators
- Improved Blood Biochemical Parameter
- Improved Blood Biochemistry
- Improved Blood Clinical Chemistry
- Improved Blood Lipid Profile
- Improved Body Mass Index
- Improved Carbohydrate Metabolism
- Improved Cardiometabolic Health
- Improved Child-Pugh Score
- Improved Cholesterol Profile
- Improved Cholesterol Regulation
- Improved Circadian-Metabolic Function
- Improved Detoxification
- Improved Dyslipidemia
- Improved Effectiveness in Nonalcoholic Steatohepatitis
- Improved Energy Metabolism in White Adipose Tissue
- Improved Estimated VO2max
- Improved Fatty Acid Oxidation
- Improved Fibrosis
- Improved Glutathione Level
- Improved Gut Microbiota-Related Pathways
- Improved Hepatic Damage
- Improved Hepatic Insulin Sensitivity
- Improved Hepatic Steatosis Severity
- Improved Hepatopancreas Health
- Improved High-Intensity Intermittent Exercise Performance
- Improved Insulin Resistance
- Improved Insulin Sensitivity
- Improved Leptin Secretion
- Improved Lipid Levels
- Improved Lipid Metabolism
- Improved Lipid Profile
- Improved Liver Biomarkers
- Improved Liver Disease Biomarkers
- Improved Liver Enzyme Activity
- Improved Liver Fatty Acid Composition
- Improved Liver Steatosis
- Improved MASH Resolution
- Improved Metabolic Activity of Bacillus coagulans
- Improved Metabolic Disease Markers
- Improved Metabolic Disorders
- Improved Metabolic Function
- Improved Metabolic Health
- Improved Metabolic Homeostasis
- Improved Metabolic Parameters
- Improved Metabolic Pathway Functions in Intestinal Microbiota
- Improved Metabolic Profile
- Improved Metabolic Regulation
- Improved Metabolic Syndrome Remission
- Improved Metabolism
- Improved Metabolism of Host-Derived Glycans
- Improved Metabolome Profile
- Improved Microbial Metabolism Regulation
- Improved NAFLD
- Improved Nutrient Metabolism
- Improved Nutritional Metabolism
- Improved Obesity Metrics
- Improved Obesity Parameters
- Improved Organ Histology
- Improved Oxidative Metabolism Regulation
- Improved Oxidative Stress Marker
- Improved Plasma Lipid Levels
- Improved Redox Homeostasis
- Improved Satiety Hormonal Status
- Improved Satiety Index
- Improved Serum Parameters
- Improved Systemic Health
- Improved Systemic Metabolism
- Improved Total Antioxidant Capacity
- Improved Total Antioxidative Status
- Improved Total Cholesterol Levels
- Improved Triglyceride Levels
- Improved VLDL Cholesterol
- Improved Waist-to-Hip Ratio
- Improved Weight Management
- Increased Aspartate Aminotransferase Concentration
- Increased Aspartate Aminotransferase Level
- Increased Aspartate Transferase Level
- Increased Betaine Content
- Increased Bioactivity
- Increased Body Mass
- Increased Body Mass Index
- Increased Body Weight Gain
- Increased Branched Chain Amino Acid Levels
- Increased CPT1 Protein Levels
- Increased Cholesterol Excretion
- Increased Cysteine Level
- Increased Daily Weight Gain
- Increased Dicarboxylic Fatty Acid Level
- Increased Fasting Insulin Level
- Increased Fatty Acid Oxidation
- Increased Fecal Triglyceride Levels
- Increased Free Fatty Acid Levels
- Increased GLP-1 Levels
- Increased Glucagon-Like Peptide 1 Level
- Increased Glycine Level
- Increased Hydroxy Fatty Acid Level
- Increased IPA Levels
- Increased Inhibition of Lipid Oxidation
- Increased Insulin Level
- Increased Insulin Resistance Level
- Increased Leptin Level
- Increased Muscle Fat Content
- Increased Nitrogen Degradation Postprandially
- Increased Physical Activity
- Increased Plasma ApoA-V Levels
- Increased Plasma GLDH
- Increased Polyphenol Level
- Increased Propionate Production
- Increased Serum Ferritin Level
- Increased Serum Triglycerides
- Increased Solid Non-Fat Content
- Increased Total Body Iron Level
- Increased Triglyceride Level
- Increased Uncoupling Protein 2 Expression
- Increased Uncoupling Protein 2 Level
- Increased Visceral Fat Mass
- Increased Weight
- Influence on Metabolic Pathways
- Maintained Metabolic Homeostasis
- Maintained Safety with Repeated Oral Exposure
- Modified Serum Metabolomic Pathways
- Modulated Liver Metabolic Pathways
- No Change in Fibrosis
- No Change in Metabolic Health
- No Significant Change in Aflatoxin Distribution or Metabolism
- Normalization of Blood Biochemical Parameters
- Normalized Lipid Metabolism
- Normalized Serum Lipid Levels
- Preserved Liver Structure
- Prevented Liver Fibrosis
- Prevention of Liver Steatosis
- Prevention of Nonalcoholic Fatty Liver Disease
- Promoted Weight Gain
- Reduced Abdominal Adiposity
- Reduced Abdominal Fat
- Reduced Adipocyte Hypertrophy
- Reduced Adipocyte Senescence
- Reduced Adipsin Level
- Reduced Adverse Physiometabolic Effects
- Reduced Anticoagulation / Increased Warfarin Variability
- Reduced Apolipoprotein B to A-1 Ratio
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Arterial Stiffness
- Reduced Aspartate Aminotransferase to Alanine Aminotransferase Ratio
- Reduced Blood Ammonia Level
- Reduced Blood Glucose Levels
- Reduced C-Reactive Protein Level
- Reduced Cholesterol Metabolism
- Reduced Circulating Endotoxin
- Reduced Diabetes Incidence
- Reduced Dietary Advanced Glycation End Product Intake
- Reduced Dimethyl Sulfide Level
- Reduced Dyslipidemia Parameters
- Reduced Dyslipidemia in Metabolic Syndrome
- Reduced Epididymal Fat Tissue Accumulation
- Reduced Fasting Insulin Level
- Reduced Fat Gain
- Reduced Flavonifractor Abundance
- Reduced GLP-1 Levels
- Reduced Glucuronide Metabolite Level
- Reduced Glycative Stress Marker Level
- Reduced HDL Cholesterol Level
- Reduced HDL Levels
- Reduced HOMA-IR
- Reduced Harmful Lipid Levels
- Reduced Hepatic Fat Accumulation
- Reduced Hepatic Inflammation and Oxidative Stress
- Reduced Hepatic Insulin Resistance
- Reduced Hepatic Lipogenesis
- Reduced Hepatic Steatosis Severity
- Reduced Hepatic Stellate Cell Activation
- Reduced Hepatic Triglyceride Levels
- Reduced Hepatocellular Carcinoma Recurrence
- Reduced Hepatocyte Ballooning
- Reduced High-Density Lipoprotein (HDL) Cholesterol
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Homeostatic Model Assessment for Insulin Resistance
- Reduced Incidence of Abnormal Increase in Alkaline Phosphatase
- Reduced Incidence of Liver Cancer
- Reduced Insulin Response
- Reduced Insulin Sensitivity
- Reduced Intracellular Triglyceride Levels
- Reduced LDL Cholesterol
- Reduced Liver Cholesterol
- Reduced Liver Cholesterol Content
- Reduced Liver Disease Progression
- Reduced Liver Fat
- Reduced Liver Fat Accumulation
- Reduced Liver Fat Content
- Reduced Liver Fat Deposition
- Reduced Liver Fat Formation
- Reduced Liver Fibrosis
- Reduced Liver Inflammation Fibrosis Score
- Reduced Liver Injury Marker
- Reduced Liver Stiffness
- Reduced Liver Triglycerides
- Reduced Lysophosphatidylethanolamine 18:1 Level
- Reduced Macrophage Infiltration in Adipose Tissue
- Reduced Mesenteric Adipose Tissue Accumulation
- Reduced Metabolic Disease Risk
- Reduced Metabolic Disorders Incidence
- Reduced Metabolic Dysregulation
- Reduced Metabolic Endotoxemia
- Reduced Metabolic Function
- Reduced Metabolic Inflammation
- Reduced N-terminal Pro-B-type Natriuretic Peptide Level
- Reduced NAFLD Activity Score
- Reduced NASH Activity
- Reduced Obesity-Related Taxa
- Reduced Oleic Acid-Induced Triglyceride Accumulation
- Reduced Oxidative Stress Marker
- Reduced Plasma Non-Esterified Fatty Acid Concentrations
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postprandial Glycemic Response
- Reduced Postprandial Insulin
- Reduced Postprandial Insulin Response
- Reduced Postprandial Triacylglycerol Response
- Reduced Procollagen Type 1 N-terminal Propeptide Level
- Reduced Serpin Level
- Reduced Serum Glycerophospholipid Levels
- Reduced Serum Lipid Levels
- Reduced Steatohepatitis
- Reduced Steatosis
- Reduced Steatosis Score
- Reduced Stigmasterol Level
- Reduced Sugar-Sweetened Beverage Intake
- Reduced Symptoms Associated with High-Fat Diet
- Reduced Systemic Endotoxemia at Rest
- Reduced TMAO Level
- Reduced Total Blood Cholesterol
- Reduced Triglycerides
- Reduced Urea Level
- Reduced Visceral Fat
- Reduced Visceral Fat Accumulation
- Reduced Visceral Fat Area
- Reduced Visceral Fat Mass
- Reduced Waist Circumference
- Reduced Waist-to-Height Ratio
- Reduced hsCRP Level
- Regulated Lipid Metabolism
- Regulated Lipid Metabolism in Epididymal Fat Pads
- Regulated Metabolic Function
- Restored Lipid Metabolism
- Reversed Microbiome Metabolic Changes
- Stabilized Visceral Fat Area
- Stable High-Density Lipoprotein Cholesterol Level
- Suppressed PPAR/SREBP Pathway Gene Activity
- Unchanged Insulin Sensitivity
- Unchanged Serum Cholesterol Levels
- Weight Gain Consistency